Study on Bevacizumab and Drug Combination for Patients with Resectable Colorectal Peritoneal Metastases

4 1 1 1

What is this study about?

This clinical trial is focused on studying treatments for peritoneal metastases that originate from colorectal cancer. Peritoneal metastases occur when cancer cells spread to the lining of the abdomen. The study involves a combination of surgery and various medications to see if this approach can improve patient outcomes. The medications being tested include Avastin (bevacizumab), Leucovorin-Teva (folinic acid), Oxaliplatin Eugia (oxaliplatin), Xeloda (capecitabine), 5-Fluorouracil Sandoz (fluorouracil), and Irinotecan Mylan Generics (irinotecan hydrochloride trihydrate). These medications are used in combination to target cancer cells and are administered either intravenously or orally.

The purpose of this study is to compare the effectiveness of chemotherapy and immunotherapy given before and after surgery with the standard approach of surgery alone. The study aims to determine if the additional treatments can improve overall survival rates for patients. Participants will receive treatment over a period of up to 12 months, with regular monitoring to assess the safety and effectiveness of the therapies. The study is designed to explore whether the combination of these treatments can provide better outcomes than surgery alone.

Throughout the study, participants will undergo various procedures, including HIPEC (Hyperthermic Intraperitoneal Chemotherapy), which involves applying heated chemotherapy directly into the abdominal cavity during surgery. This approach aims to kill any remaining cancer cells after the tumor has been surgically removed. The trial is structured to ensure that all participants receive the best possible care while contributing to important research that could benefit future patients with similar conditions.

1 enrollment and initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and diagnostic tests such as laparoscopy or imaging scans to ensure the disease is resectable.

Eligibility criteria include a performance status of 0 or 1, confirmed diagnosis of colorectal cancer with peritoneal metastases, and no recent systemic therapy or other interfering conditions.

2 preoperative systemic therapy

The treatment begins with preoperative systemic therapy, which involves administering a combination of medications to manage the cancer before surgery.

Medications include bevacizumab (Avastin) administered intravenously, folinic acid (Leucovorin) intravenously, oxaliplatin intravenously, capecitabine (Xeloda) taken orally, fluorouracil intravenously, and irinotecan intravenously.

The specific dosage and frequency are determined by the medical team based on individual patient needs.

3 surgical intervention

Following the systemic therapy, a surgical procedure known as cytoreductive surgery is performed to remove visible tumors.

This surgery is combined with a treatment called HIPEC (Hyperthermic Intraperitoneal Chemotherapy), where heated chemotherapy is applied directly to the abdominal cavity to target remaining cancer cells.

4 postoperative systemic therapy

After surgery, additional systemic therapy may be administered to further reduce the risk of cancer recurrence.

The same medications used in the preoperative phase may be continued, with adjustments made as necessary based on the patient’s response and recovery.

5 follow-up and monitoring

Regular follow-up appointments are scheduled to monitor recovery and assess the effectiveness of the treatment.

These appointments may include physical examinations, imaging tests, and laboratory tests to check for any signs of cancer recurrence.

Who Can Join the Study?

The patient must have resectable peritoneal metastases from colorectal cancer. This means the cancer has spread to the lining of the abdomen but can be surgically removed.
The patient must have a World Health Organisation (WHO) performance status of 0 or 1. This is a scale that measures how well a patient can perform daily activities. A score of 0 means fully active, and 1 means some symptoms but still able to do light work.
The patient must have proof of cancer through a histological or cytological test. This means the cancer cells have been examined under a microscope.
The cancer must be a type called non-appendiceal colorectal adenocarcinoma, with no more than 50% of the tumor cells being signet ring cells. These are specific types of cancer cells.
The disease must be confirmed as resectable through a diagnostic laparoscopy/laparotomy and imaging tests like CT or MRI. These are procedures and scans to check if the cancer can be removed.
There must be no signs of cancer spreading to other parts of the body within three months before joining the study.
The patient must not have received any systemic therapy for colorectal cancer in the six months before joining the study. Systemic therapy is treatment that affects the entire body, like chemotherapy.
The patient must not have any medical reasons that would prevent them from undergoing CRS-HIPEC. This is a specific type of surgery and chemotherapy treatment.
The patient must not have had CRS-HIPEC before.
The patient must not have any other cancers that would interfere with the study treatment or affect the outcome of the surgery for colorectal cancer.
Both male and female patients are eligible to participate.
The study is open to adults, typically those aged 18 and older.

Who Cannot Join the Study?

Patients with medical conditions other than resectable peritoneal metastases of a colorectal origin cannot participate. This means the cancer has spread to the lining of the abdomen and can be surgically removed, and it started in the colon or rectum.
Patients who are not within the specified age range cannot participate. The age range is typically defined in the study details.
Patients who are part of a vulnerable population cannot participate. Vulnerable populations include groups like children, pregnant women, or those unable to give consent.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country
Universitair Medisch Centrum Utrecht	Utrecht	The Netherlands
Catharina Ziekenhuis Stichting	Eindhoven	The Netherlands
Stichting Radboud University Medical Center	Nijmegen	The Netherlands
St. Antonius Ziekenhuis	Nieuwegein	The Netherlands
Ziekenhuis Oost Limburg	Genk	Belgium
Netherlands Cancer Institute	Amsterdam	The Netherlands
Ufmsafdlwivl Mkdtkay Ciiuese Gvoxdyqkz	Groningen	The Netherlands
Ennfbse Uulohwmaific Myyfpoy Cxyiniv Rclbytaky (ojyqlnd Mfb	Rotterdam	The Netherlands
Azkhysucb Uxo	Amsterdam	The Netherlands

Trial status

Country	Status	Recruitment Start
Belgium	Not yet recruiting	15.06.2017
The Netherlands	Not yet recruiting	15.06.2017

Trial locations

Investigated drugs:

Perioperative Systemic Therapy is a treatment given around the time of surgery to help shrink tumors and kill cancer cells. It is used in this trial to see if it can improve outcomes for patients with colorectal cancer that has spread to the lining of the abdomen. This therapy is given before and after surgery to help reduce the risk of cancer returning.

Cytoreductive Surgery with HIPEC involves surgically removing as much of the cancer as possible, followed by a special type of chemotherapy called Hyperthermic Intraperitoneal Chemotherapy (HIPEC). During HIPEC, heated chemotherapy is delivered directly into the abdominal cavity to target any remaining cancer cells. This approach is used to treat colorectal cancer that has spread to the peritoneum, aiming to improve survival and reduce recurrence.

Investigated diseases:

Resectable Peritoneal Metastases of a Colorectal Origin – This condition occurs when cancer cells from the colon or rectum spread to the peritoneum, which is the lining of the abdominal cavity. These metastases are considered resectable, meaning they can potentially be removed through surgery. The disease progresses as cancer cells continue to grow and spread within the peritoneal cavity, potentially affecting other organs. Symptoms may include abdominal pain, bloating, and changes in bowel habits. The progression of the disease can lead to increased discomfort and complications related to the abdominal organs.

Trial ID:

2024-518570-13-00

NCT ID:

NCT02758951

Trial Phase:

Therapeutic use (Phase IV)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Bevacizumab and Drug Combination for Patients with Resectable Colorectal Peritoneal Metastases

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?